Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2024-04-25 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于2021年股票期权与限制性股票激励计划第一次预留授予部分第三个行权期行权条件及第三个解除限售期解除限售条件未成就暨注销股票期权和回购注销限制性股票的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement from 哈药集团股份有限公司 regarding the 2021 stock option and restricted stock incentive plan, specifically about the failure to meet certain performance conditions for the third exercise and lifting of restrictions period, resulting in the cancellation of stock options and repurchase and cancellation of restricted stocks. It includes detailed descriptions of board and supervisory committee meetings, legal opinions, and the impact on share structure. The document is not a full annual or interim financial report, nor is it a simple announcement of a report. It is focused on management decisions related to stock incentive plans and their execution, including board and supervisory committee approvals and legal opinions. This fits best under Board/Management Information (MANG) as it relates to management decisions and board resolutions about stock incentive plans and cancellations. The document length (9516 characters) and content confirm it is not a brief announcement or a certification but a substantive management-related disclosure.
2024-04-25 Chinese
哈药集团股份有限公司十届三次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) regarding multiple agenda items approved in the third meeting of the tenth board of directors. It includes approval of the 2024 first quarter report and several resolutions related to stock option and restricted stock incentive plans, including cancellations and repurchases. The document references that the detailed 2024 first quarter report is disclosed separately on the Shanghai Stock Exchange website, indicating this document itself is not the full quarterly report but a board meeting announcement of resolutions. The document length is 3178 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on board decisions and approvals, especially related to stock incentives and the quarterly report approval, which fits the category of Board/Management Information (MANG). It is not a full financial report (IR), nor a proxy or voting result announcement. Therefore, the best classification is MANG with high confidence.
2024-04-25 Chinese
哈药集团股份有限公司关于回购注销部分限制性股票通知债权人的公告
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement from 哈药集团股份有限公司 regarding the repurchase and cancellation of restricted shares under the 2021 stock option and restricted stock incentive plan. It details the number of shares to be repurchased, the prices, and the legal procedures including notification to creditors about the reduction in registered capital. The document is a notification about a share repurchase and capital reduction event, not a financial report or earnings release. It does not contain financial statements or management discussion but focuses on the share repurchase and cancellation process. Therefore, it fits the category of Transaction in Own Shares (POS). The document length is 2191 characters, which is consistent with an announcement rather than a full report.
2024-04-25 Chinese
哈药集团股份有限公司关于2021年股票期权与限制性股票激励计划首次授予部分第三个行权期行权条件及第三个解除限售期解除限售条件未成就暨注销股票期权和回购注销限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 哈药集团股份有限公司 regarding the 2021 stock option and restricted stock incentive plan, specifically about the failure to meet certain performance conditions for the third exercise and release periods, resulting in the cancellation of stock options and repurchase and cancellation of restricted stocks. It includes detailed descriptions of board and supervisory committee meetings, legal opinions, and the impact on share structure. The document is not a full annual or interim financial report, nor is it a simple announcement of a report. It is a formal announcement about changes in stock options and restricted stock incentives, which relates to capital structure changes and financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to the specificity and detailed nature of the content about stock option cancellations and repurchases.
2024-04-25 Chinese
哈药集团股份有限公司关于2021年股票期权与限制性股票激励计划剩余预留授予部分第二个行权期行权条件及第二个解除限售期解除限售条件未成就暨注销股票期权和回购注销限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 哈药集团股份有限公司 regarding the 2021 stock option and restricted stock incentive plan, specifically about the failure to meet certain performance conditions, resulting in the cancellation of stock options and repurchase and cancellation of restricted stocks. It includes detailed descriptions of board and supervisory committee meetings, legal opinions, and the impact on share structure. The document is not a full annual or interim financial report, nor is it a simple announcement of a report. It is a regulatory announcement about stock option and restricted stock incentive plan adjustments and cancellations, which is a capital structure related update. Therefore, it fits best under Capital/Financing Update (CAP). The document length is substantial (9500 characters), and it contains substantive content about financing-related corporate actions rather than just a brief announcement or certification. Hence, the classification is CAP with high confidence.
2024-04-25 Chinese
北京市天元律师事务所上海分所关于哈药集团股份有限公司2021年股票期权与限制性股票计划注销部分股票期权及回购注销部分限制性股票相关事宜的法律意见
Regulatory Filings
2024-04-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.